Issue 30, 2016

How can nanomedicines overcome cellular-based anticancer drug resistance?

Abstract

Despite the great progress in the field of cancer research, complete remission of cancer patients is a rarely seen outcome in clinics. The failure of a plethora of promising anticancer drugs is mostly due to the insurgence of multidrug resistance (MDR) phenomena with various factors, both physio-pathological and cellular, being responsible for their development. Over the past 40 years, the impressive progress in the nanotechnology field and its application in medicine (i.e., nanomedicine) enabled the development of novel cancer treatments with improved specificity and efficacy, mainly referring to the possibility to overcome MDR. However, the emergence of many nanomedicines defined in the literature as “overcoming the resistance” has resulted in very few of them eventually being approved for clinical application and reaching the marketplace (liposomal formulation of doxorubicin (Myocet®, Caelix®) and paclitaxel nanoparticles (Abraxane®), for instance). The capacity of nanomedicines to overcome physio-pathological-based resistance by enhancing drug accumulation at the tumor site via passive and ligand-mediated targeting has been largely reviewed in the past few years. This review will specifically focus on the cellular mechanisms involved in the MDR, which will be discussed with respect to the cellular site in which their action is exerted (that is, membrane, cytoplasm or nucleus). A complete overview of various nanomedicines designed to bypass or directly inhibit each of these specific resistance mechanisms will be offered.

Graphical abstract: How can nanomedicines overcome cellular-based anticancer drug resistance?

Article information

Article type
Review Article
Submitted
11 Apr 2016
Accepted
17 Jun 2016
First published
04 Jul 2016

J. Mater. Chem. B, 2016,4, 5078-5100

How can nanomedicines overcome cellular-based anticancer drug resistance?

D. Sobot, S. Mura and P. Couvreur, J. Mater. Chem. B, 2016, 4, 5078 DOI: 10.1039/C6TB00900J

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements